A'
Therapeutic Areas
Aytu BioPharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EXXUA™ (gepirone ER) | Major Depressive Disorder (MDD) | Commercial |
| ADHD Portfolio (e.g., Karbinal™ ER) | Attention-Deficit/Hyperactivity Disorder (ADHD) | Commercial |
| Pediatric Portfolio (e.g., Poly-Vi-Flor®) | Fluoride Deficiency / ADHD Support | Commercial |
| Legacy Portfolio (e.g., Natesto®) | Allergies, Hypogonadism | Commercial |
Leadership Team at Aytu BioPharma
JD
Josh Disbrow
Chief Executive Officer & Director
RS
Ryan Selhorn
Chief Financial Officer
GP
Greg Pyszczymuka
Chief Commercial Officer
JD
Jarrett Disbrow
Chief Business Officer
DG
Dr. Gerwin Westfield
Senior VP of Scientific Affairs
MC
Margaret Cabano
Senior VP of Operations
SK
Suzane Kennedy
VP of Regulatory Affairs and Quality Assurance
JD
John Donofrio, Jr.
Chairman of the Board, Audit Committee Chair
CD
Carl Dockery
Director, Nominating & Governance Committee Chair
VL
Vivian Liu
Director, Compensation Committee Chair